LncRNAs and their role in cancer stem cells

Chen, Shusen; Zhu, Jiamin; Wang, Feng; Guan, Zhifeng; Ge, Yangyang; Yang, Xi; Cai, Jing

doi:10.18632/oncotarget.22161

Cited by 84 publications

(59 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Knocking down HOTAIR inhibits features of TICs including frequencies of side population cells and spheroid forming cells [88]. Chen and colleagues recently reviewed regulations of lncRNAs in TICs in several types of cancers [89]. Thus, it is imperative to find whether these lncRNAs are able to affect TICs involved in lung tumorigenesis to find avenues of targeting these lncRNAs.…”

Section: Role Of Non-coding Rnas In Lung Tumor Initiating Cellsmentioning

confidence: 99%

“…It is imperative that lncRNAs are studied to further our understanding of their mechanisms of action within lung cancer, especially since lncRNAs and miRNAs have been found to affect each other and lung cancer overall, as exemplified by RNA component of mitochondrial RNA processing endoribonuclease being able to affect miR-206 levels to activate oncogenes in lung cancer (see Table 2). As shown before, literature reviews such as "Long noncoding RNAs as regulators of cancer immunity" have summarized the role of non-coding RNAs in other types of cancers, and researchers can use this information to determine whether those non-coding RNAs are also able to affect lung cancer [89,163,185]. Furthermore, new and emerging technologies such as RNA editing and RNA modification warrant further research as they too have been implicated in altering lncRNAs and miRNAs to either promote or impede lung tumor initiation and progression.…”

Section: Concluding Remarks and Future Directionmentioning

confidence: 99%

See 1 more Smart Citation

Non-Coding RNAs in Lung Tumor Initiation and Progression

Santos

Moreno

Zhang

2020

IJMS

View full text Add to dashboard Cite

Lung cancer is one of the deadliest forms of cancer affecting society today. Non-coding RNAs, such as microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), through the transcriptional, post-transcriptional, and epigenetic changes they impose, have been found to be dysregulated to affect lung cancer tumorigenesis and metastasis. This review will briefly summarize hallmarks involved in lung cancer initiation and progression. For initiation, these hallmarks include tumor initiating cells, immortalization, activation of oncogenes and inactivation of tumor suppressors. Hallmarks involved in lung cancer progression include metastasis and drug tolerance and resistance. The targeting of these hallmarks with non-coding RNAs can affect vital metabolic and cell signaling pathways, which as a result can potentially have a role in cancerous and pathological processes. By further understanding non-coding RNAs, researchers can work towards diagnoses and treatments to improve early detection and clinical response.

show abstract

Section: Role Of Non-coding Rnas In Lung Tumor Initiating Cellsmentioning

confidence: 99%

Section: Concluding Remarks and Future Directionmentioning

confidence: 99%

Non-Coding RNAs in Lung Tumor Initiation and Progression

Santos

Moreno

Zhang

2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Components of dysregulated CSC-enriched molecular pathways (e.g., Notch, Wnt, and Hh) may exemplify novel druggable targets for signaling antagonists [16,39,40]. Additionally, increasing evidence suggests that it may be possible to target CSCs via CSC-specific or associated non-coding RNAs [41][42][43][44].…”

mentioning

confidence: 99%

The Missing Lnc: The Potential of Targeting Triple-Negative Breast Cancer and Cancer Stem Cells by Inhibiting Long Non-Coding RNAs

Brown

Wasson

Marcato

2020

Cells

View full text Add to dashboard Cite

Treatment decisions for breast cancer are based on staging and hormone receptor expression and include chemotherapies and endocrine therapy. While effective in many cases, some breast cancers are resistant to therapy, metastasize and recur, leading to eventual death. Higher percentages of tumor-initiating cancer stem cells (CSCs) may contribute to the increased aggressiveness, chemoresistance, and worse outcomes among breast cancer. This may be particularly true in triple-negative breast cancers (TNBCs) which have higher percentages of CSCs and are associated with worse outcomes. In recent years, increasing numbers of long non-coding RNAs (lncRNAs) have been identified as playing an important role in breast cancer progression and some of these have been specifically associated within the CSC populations of breast cancers. LncRNAs are non-protein-coding transcripts greater than 200 nucleotides which can have critical functions in gene expression regulation. The preclinical evidence regarding lncRNA antagonists for the treatment of cancer is promising and therefore, presents a potential novel approach for treating breast cancer and targeting therapy-resistant CSCs within these tumors. Herein, we summarize the lncRNAs that have been identified as functionally relevant in breast CSCs. Furthermore, our review of the literature and analysis of patient datasets has revealed that many of these breast CSC-associated lncRNAs are also enriched in TNBC. Together, this suggests that these lncRNAs may be playing a particularly important role in TNBC. Thus, certain breast cancer-promoting/CSC-associated lncRNAs could be targeted in the treatment of TNBCs and the CSCs within these tumors should be susceptible to anti-lncRNA therapy.

show abstract

“…Recently, numerous studies revealed that various lncRNAs could regulate cancer stem cell (CSC) in numerous types of cancer via different molecular mechanisms, which involve differentiation, proliferation and self-renewal, promotion of the metastasis, invasion and prediction of prognosis, and targeted therapies. To date, ROR, HOTAIR, H19, UCA1, and ARSR are the most highlighted lncRNAs in CSCs [17]. Therefore, lncRNAs could be used as a new master regulators of resistance to systemic treatments in BC [18].…”

Section: Discussionmentioning

confidence: 99%

Long non-coding RNA ROR accelerates the progression of breast cancer via promoting stemness in MCF-10A cells

S.Wang¹,

Chen²,

Song³

et al. 2020

EJGO

View full text Add to dashboard Cite

Long non-coding RNA (lncRNA), regulator of reprogramming (ROR) is an intergenic lncRNA previously shown to contribute to tumorigenesis in several malignancies. In their previous study, the present authors found that ROR was highly associated with gastric cancer progression, however, the role of ROR in breast cancer (BC) was still unclear. Here, the authors investigated the role and mechanism of ROR in BC. They found that the expression of ROR was increased in the MCF-7 cells and MDA-MB-231 cells compared with the control MCF-10A. The exogenous expression of ROR was increased using plasmid overexpressing ROR in MCF-10A cells, then the biological function of ROR was determined using MTT assay and Transwell assay. The result indicated that overexpression of ROR could significantly increase the capability of cell proliferation and invasion. Furthermore, the molecular markers for BC stem cell (BCSC) were verified, the results showed that enhanced expression of cluster of differentiation 44 (CD44) and aldehyde dehydrogenase 1 (ALDH1) was observed in MCF-10A cells with ROR overexpression. In summary, this study will further expand our understanding of ROR and provide a new target for the treatment of BC.

show abstract

LncRNAs and their role in cancer stem cells

Cited by 84 publications

References 72 publications

Non-Coding RNAs in Lung Tumor Initiation and Progression

Non-Coding RNAs in Lung Tumor Initiation and Progression

The Missing Lnc: The Potential of Targeting Triple-Negative Breast Cancer and Cancer Stem Cells by Inhibiting Long Non-Coding RNAs

Long non-coding RNA ROR accelerates the progression of breast cancer via promoting stemness in MCF-10A cells

Contact Info

Product

Resources

About